US EditionPublished • loading... • Updated
Angelini Partners with Quiver on AI-Driven Discovery in Genetic Epilepsies - European Biotechnology Magazine
Summary by European-biotechnology.com
4 Articles
4 Articles
Angelini partners with Quiver on AI-driven discovery in genetic epilepsies - European Biotechnology Magazine
Italy’s Angelini Pharma has signed a multi-year research collaboration and licensing agreement with Massachusetts-based Quiver Bioscience to discover new treatments for genetic epilepsies, including developmental and epileptic encephalopathies (DEEs). Under the agreement, Quiver could receive up to $120 million in milestone payments plus royalties if Angelini advances drug targets emerging from the collaboration. Financial terms for the upfront …
Coverage Details
Total News Sources4
Leaning Left1Leaning Right1Center1Last UpdatedBias Distribution34% Left, 33% Center, 33% Right
Bias Distribution
- 34% of the sources lean Left, 33% of the sources are Center, 33% of the sources lean Right
34% Left
L 34%
C 33%
R 33%
Factuality
To view factuality data please Upgrade to Premium
